Vesta Corporation is a fintech company headquartered in Oregon, USA. It was founded in 1995 and has established itself as a leader in the field of payment fraud prevention. It specializes in serving the telecommunications industry, particularly prepaid wireless services and MVNOs. Its core platform integrates AI-powered payment processing, real-time risk decisioning, and fraud protection. Key offerings include Payment Guarantee™ (100% fraud chargeback guarantee for zero-risk transactions), risk scoring, and optimization for card-not-present (CNP) transactions. Leveraging over 25 years of data and processing more than $4 billion in transactions annually, it helps major carriers (e.g., AT&T, Vodafone) recover 2–5% of lost revenue. The company serves over 40 countries and handles more than 100 million transactions per year, making it a global leader in telecom fraud prevention and payments.

OriGene Technologies was founded in 1996 and is headquartered in Rockville, Maryland, USA. It is a globally leading gene-centric life sciences company specializing in genomic and proteomic research tools. The company possesses one of the world’s largest commercial collections of full-length human cDNA clones (over 580,000), and has developed more than one million research products. These include highly validated antibodies (monoclonal and polyclonal), full-length recombinant human proteins (covering over 50% of the human proteome), lentiviruses, CRISPR tools, shRNA, stable cell lines, tissue banks, and custom services. Its mission is to provide high-quality proteins and antibodies—one target at a time—to accelerate scientific breakthroughs and the development of novel diagnostics. For over 25 years, it has served academic institutions, pharmaceutical companies, and diagnostic organizations worldwide.

Sirnaomics is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Maryland, United States, with branches in Boston (USA), Hong Kong, Guangzhou, and Suzhou in China.

Sirnaomics is the first to achieve positive Phase IIb clinical outcomes in oncology clinical-stage RNA therapeutics. It is a biopharmaceutical company with a strong presence in both Asia and the U.S. that is discovering and developing innovative drugs for significant unmet medical needs and large market opportunities. They have built a professional international team for the discovery and development of RNAi therapeutics and mRNA vaccines and therapeutics, based on their proprietary drug delivery technology platforms.

Sirnaomics was listed on the Hong Kong Stock Exchange at the end of 2024. Its clinical pipeline of small interfering RNA (siRNA) therapeutics primarily focuses on oncology. The company possesses unique patented technologies for targeted drug delivery into the nuclei of tumor cells, enabling precision treatment. Its representative drug candidates, STP705 and STP707, are both currently in Phase II clinical trials.

Ark Pacific Special Opportunities Fund focuses on identifying opportunities and investing in equities across the Asia-Pacific region. The fund holds shares in companies such as Comtec Solar Systems Group Ltd, a Hong Kong-listed company, and others. The market value of its holdings in Comtec Solar alone exceeds 7 million USD.

In 2001, Beijing Geyuan Investment Consulting Co., Ltd., through its controlling subsidiary Sinoway Investment Corporation, invested in KunMing Sinobright Department Store Co., Ltd. (stock code: 000560), Yunnan’s largest commercial enterprise listed on the Shenzhen Stock Exchange, with total assets exceeding 1.3 billion RMB. At that time, the company was deeply mired in massive debt, insolvent, and on the verge of bankruptcy. After Sinoway Investment Corporation took control, it promoted debt restructuring, institutional reforms, and other self-rescue measures. The company cut hundreds of cash-burning projects that were draining its resources, redirected its limited funds and talent to focus on its core department store and hotel businesses, and gradually turned losses into profits. Subsequently, Mr. Dao Feng He once again drove asset mergers and acquisitions as well as restructuring for KunMing Sinobright Department Store Co., Ltd., which significantly improved the company’s cash position and led to a substantial increase in its market capitalization.

Kunming Sinoway Natural Pharmaceuticals Co., Ltd. was founded in 1998 and is a high-tech pharmaceutical enterprise integrating the research and development, production, and sales of chemical preparations, traditional Chinese medicines, and biopharmaceuticals. It was invested in and acquired by Sinoway Investment Corporation in 1998 and has gradually developed into a modern pharmaceutical company specializing in macromolecular biologics and chemical drugs.

Sinoway Pharmaceutical’s core therapeutic areas include cardiovascular and cerebrovascular diseases, digestive system disorders and wound repair, anti-hepatitis B antiviral treatments, orthopedics and trauma, as well as topical medications. Its representative products include Kangfuxin Ye (Rehabilitation New Liquid, a nationally protected traditional Chinese medicine), Ganlong Capsules (a national Class II new drug), Xinluoping (an innovative antihypertensive drug), Yimaikang Tablets, Xibi Yi (a patented nasal wash product), Ningxinbao (Cordyceps sinensis refined capsules), and others.

With its core competitiveness centered on distinctive traditional Chinese medicine combined with innovative R&D, Sinoway Pharmaceutical is developing toward large-scale and innovation-driven growth, aiming to become a representative biopharmaceutical enterprise in Yunnan.

Shanghai Purun Phase IV Equity Investment Partnership Enterprise, founded in 2016, is a professional investment institution specializing in growth-stage equity investment and strategic integration.

The Company’s core business encompasses equity investment, investment management, asset management, and venture capital, with a primary focus on leading entrepreneurial companies in advanced manufacturing, modern services, healthcare, and consumer sectors. By managing both RMB and USD investment funds, the Company provides professional capital operation services to its investors.

In its equity investment practice, the company relies on in-depth industry research and strong resource integration capabilities to implement a value-driven investment strategy supported by a systematic post-investment management system. Through the operation of a professional team, the Company has accumulated extensive investment experience in relevant fields and established a robust risk control mechanism.

Key portfolio companies include: Zhejiang Huayuan Automotive Technology Co., Ltd. (listed on the Shenzhen Stock Exchange in 2025), Daosheng Advanced Materials Technology (Shanghai) Co., Ltd. (listed on the Shanghai Stock Exchange in 2025), and others.

Tianjin Shangshi Venture Investment Fund is a professional investment fund established within China’s private equity and venture capital ecosystem, managed by Beijing Shangshi Investment Management Co., Ltd. Founded in 2014, Shangshi Capital manages multiple RMB and USD-denominated funds, with total assets under management exceeding 1.5 billion RMB. The fund primarily focuses on early and growth-stage investments (Seed to Series B), with key sectors including digital healthcare and life sciences, consumer upgrade, Internet of Things (IoT), enterprise services, and technological innovation.

To date, Shangshi Capital has invested in more than 60 companies across sectors such as medical technology, smart hardware, and consumer technology, and has established deep collaborations with numerous domestic and international institutions.